Back to Headlines
Health
May 22, 2026
Analyzed by GPT OSS 120B

Eli Lilly’s Retatrutide Shows Record Weight‑Loss in Phase 3 Trial

AI Summary
Eli Lilly announced that its experimental triple‑agonist Retatrutide produced an average loss of 28% body weight – up to 70.3 lb – in a 80‑week Phase 3 study, far surpassing existing GLP‑1 drugs. The results could reshape the obesity‑treatment market if regulators grant approval.

Retatrutide Delivers Up to 28% Body‑Weight Reduction in Phase 3 Study

A new weight‑loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight, Eli Lilly announced on Thursday.

Phase 3 Trial Design and Dosing Regimen

The Indiana‑based company randomized 2,339 adults with obesity or overweight and at least one weight‑related comorbidity (no diabetes) to receive Retatrutide at 4 mg, 9 mg, 12 mg, or placebo for 80 weeks. The drug is a once‑weekly triple hormone receptor agonist targeting GLP‑1, GIP, and glucagon.

Quantitative Outcomes and Safety Profile

  • Average weight loss: 70.3 lb (28.3%) at the 12 mg dose.
  • Average loss at 9 mg: 64.4 lb (25.9%).
  • Average loss at 4 mg: 47.2 lb (19.0%).
  • 45.3% of 12 mg participants lost ≥30% of body weight.
  • 65.3% reduced BMI below 30; 37.5% of those starting with BMI ≥ 40 achieved this.
  • Side‑effects increased with dose: nausea (28.6%‑42.4%), diarrhea (25.2%‑34.1%), vomiting (up to 25%).

For comparison, Zepbound yields 15‑20% loss over 72 weeks and Wegovy 14‑19% over 64‑72 weeks.

Implications for the Obesity‑Drug Landscape

The magnitude of loss positions Retatrutide as the most effective pharmacologic option to date, potentially shifting prescriber preference away from existing GLP‑1 monotherapies. Its triple‑agonist mechanism adds glucagon, a hormone absent from current products, which may enhance metabolic control and appetite suppression.

Future Outlook: Approval Path and Market Potential

Analysts expect regulatory submissions within the next year, with a likely U.S. FDA review in 2027. If approved, Retatrutide could capture a sizable share of the rapidly expanding obesity‑treatment market, prompting competitors to explore multi‑agonist formulations.